Zymeworks Inc. announced on March 25, 2025, the acceptance of six abstracts for poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 24-30, 2025, in Chicago, IL. These presentations will highlight results from preclinical research across Zymeworks’ T-cell engager (TCE) and antibody-drug conjugate (ADC) platforms.
Key updates include data on ZW209, a novel DLL3-targeting trispecific T cell engager, which is on track for an Investigational New Drug (IND) submission in the first half of 2026. Additionally, preclinical findings for ZW327, a Ly6E-targeting ADC incorporating Zymeworks’ proprietary topoisomerase 1 inhibitor payload, ZD06519, will be shared.
The presentations will also cover ZW171, a mesothelin-targeting TCE currently in global Phase 1 clinical studies, and biparatopic ADCs targeting Protein Tyrosine Kinase 7 (PTK7). These findings demonstrate the potential of Zymeworks' therapeutic approaches to improve outcomes for patients with difficult-to-treat cancers by addressing critical unmet needs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.